Library

Respiratory and Antinociceptive Effects of Nociceptin Receptor-µ-Opioid Receptor Agonist Cebranopadol versus Full Opioid Receptor Agonist Oxycodone: A Comparison in Healthy Volunteers.

1 April 2026. doid: 10.1097/ALN.0000000000005894

Jansen S, Olofsen E, Moss L, Grieco JC, Lesnick ML, Hackworth JC, van Velzen M, Dahan A, Sarton E, Groeneveld GJ, Niesters M, van der Schrier R

View publication

The novel analgesic cebranopadol targets the nociceptin (NOP) and µ-opioid (MOP) receptors, acting as a novel full dual NOP-MOP receptor agonist, with possible differences in respiratory effects compared to selective MOP opioids like oxycodone.

Advancing the boundaries of clinical drug development

Wondering how we can help you? Reach out to us.

Get in contact
contact